Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atracurium besylate
Drug ID BADD_D00188
Description A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Indications and Usage For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Marketing Status approved
ATC Code M03AC04
DrugBank ID DB00732
KEGG ID D00758
MeSH ID D001279
PubChem ID 47320
TTD Drug ID D0Q1PR
NDC Product Code 55150-216; 0409-1105; 0409-1109; 71288-701; 55486-1597; 71288-702; 55150-217; 17404-0008
UNII 40AX66P76P
Synonyms Atracurium | 33 A 74 | A 74, 33 | Relatrac | Tracrium | BW-33A | BW 33A | BW33A | Atracurium Besylate | Atracurium Besilate | Besilate, Atracurium | Atracurium Dibesylate
Chemical Information
Molecular Formula C65H82N2O18S2
CAS Registry Number 64228-81-5
SMILES C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CC C5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C =C1)S(=O)(=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Bradycardia02.03.02.002--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac arrest02.03.04.001--
Cardiovascular disorder02.11.01.010; 24.03.02.009--Not Available
Dermatitis23.03.04.002--Not Available
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Flushing08.01.03.025; 24.03.01.002; 23.06.05.003--
Heart rate decreased13.14.04.001--Not Available
Heart rate increased13.14.04.002--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypotension24.06.03.002--
Hypoxia22.02.02.003--
Injection site reaction12.07.03.015; 08.02.03.014--
Laryngospasm22.04.02.002--
Mean arterial pressure13.14.03.018--Not Available
Mean arterial pressure decreased13.14.03.016--Not Available
Mean arterial pressure increased13.14.03.015--Not Available
Muscular weakness15.05.06.001; 17.05.03.005--
Myopathy15.05.05.001--Not Available
Neuromuscular block prolonged12.02.20.008; 17.05.04.005--Not Available
Neuromuscular blockade17.05.04.003--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Seizure17.12.03.001--
Tachycardia02.03.02.007--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages